MOLECULAR CANCER THERAPEUTICS

Scope & Guideline

Empowering breakthroughs in cancer research and treatment.

Introduction

Welcome to the MOLECULAR CANCER THERAPEUTICS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of MOLECULAR CANCER THERAPEUTICS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1535-7163
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2001 to 2024
AbbreviationMOL CANCER THER / Mol. Cancer Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

The journal "Molecular Cancer Therapeutics" focuses on advancing the understanding and treatment of cancer through innovative therapeutic strategies. It encompasses a wide array of research dedicated to novel agents, combination therapies, and the mechanisms underlying cancer drug resistance.
  1. Novel Therapeutic Agents:
    The journal features research on newly developed therapeutic agents, including small molecules, antibodies, and antibody-drug conjugates, aimed at targeting specific cancer types and overcoming resistance mechanisms.
  2. Combination Therapies:
    A significant focus is on combination therapies, which explore the synergistic effects of different treatment modalities, such as chemotherapy, immunotherapy, and targeted therapies, to enhance efficacy and reduce resistance.
  3. Mechanisms of Drug Resistance:
    Research delves into the molecular mechanisms that contribute to drug resistance in cancer, providing insights that can guide the development of new therapeutic strategies and improve treatment outcomes.
  4. Biomarker Identification and Validation:
    The identification and validation of biomarkers that predict response to therapies are crucial aspects of the journal, enhancing personalized medicine approaches in oncology.
  5. Preclinical and Clinical Studies:
    The journal publishes findings from both preclinical models and clinical trials, bridging the gap between laboratory research and patient care, thus facilitating the translation of scientific discoveries into therapeutic applications.
  6. Tumor Microenvironment Interactions:
    Research on the interactions between tumors and their microenvironment is emphasized, particularly how these interactions influence treatment response and resistance.
The journal has seen the emergence of several trends that indicate the future direction of cancer research and therapeutics. This section highlights the most significant emerging themes based on recent publications.
  1. Targeted Therapy Innovations:
    There is a significant trend towards the development of highly selective targeted therapies, including PROTACs and small-molecule inhibitors that address specific mutations and pathways in cancer, thereby enhancing treatment precision.
  2. Immunotherapy and Immune Modulation:
    The exploration of immunotherapy continues to gain momentum, with a focus on innovative approaches that enhance the immune response against tumors, including immune checkpoint inhibitors and T-cell engagers.
  3. Biomarker-Driven Treatment Approaches:
    Emerging research emphasizes the importance of biomarker-driven approaches to personalize cancer treatment, allowing for tailored therapies based on individual patient profiles and tumor characteristics.
  4. Nanotechnology in Cancer Therapy:
    The use of nanotechnology for drug delivery systems is on the rise, facilitating targeted and effective delivery of therapeutics to tumor sites while minimizing systemic toxicity.
  5. Exploration of Tumor Microenvironment Dynamics:
    Research increasingly focuses on understanding the tumor microenvironment's role in cancer progression and treatment response, leading to innovative strategies that target both tumor cells and their surrounding stroma.
  6. Combination of Targeted Therapies with Immunotherapy:
    There is a growing interest in the synergistic potential of combining targeted therapies with immunotherapies, which aims to enhance overall treatment efficacy and address resistance mechanisms.

Declining or Waning

As the journal evolves, certain themes may show a decrease in prominence. This section identifies areas that have gradually waned in focus, reflecting shifts in research priorities and advancements in cancer therapeutics.
  1. Traditional Chemotherapy Approaches:
    While traditional chemotherapy remains a cornerstone in cancer treatment, research focusing solely on these approaches is declining as the field shifts towards targeted therapies and immunotherapies that offer more personalized treatment options.
  2. Single-Agent Studies:
    There is a noticeable decrease in studies investigating single-agent therapies, as the trend moves towards exploring combination therapies that leverage synergistic effects for improved outcomes.
  3. Basic Science Without Therapeutic Application:
    Research that focuses primarily on basic cancer biology without direct therapeutic implications or translational relevance is becoming less prevalent, as emphasis grows on studies that can lead to practical treatments.

Similar Journals

Cancer Research and Treatment

Innovating solutions for a cancer-free tomorrow.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

ONCOGENE

Pioneering Genetic Discoveries in Oncology
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

CURRENT CANCER DRUG TARGETS

Innovating drug discovery at the forefront of cancer research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Recent Patents on Anti-Cancer Drug Discovery

Pioneering Research for a Cancer-Free Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Cancer Drug Resistance

Transforming Oncology: Tackling Drug Resistance Head-On.
Publisher: OAE PUBLISHING INCISSN: Frequency: 1 issue/year

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

ANTI-CANCER DRUGS

Transforming Insights into Effective Cancer Solutions
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Targeted Oncology

Empowering researchers to redefine cancer treatment.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

MOLECULAR CANCER RESEARCH

Transforming Research into Revolutionary Treatments
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

JOURNAL OF GENE MEDICINE

Connecting Researchers to Transformative Genetic Insights
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

SEMINARS IN CANCER BIOLOGY

Elevating knowledge in cancer mechanisms.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1044-579XFrequency: 6 issues/year

SEMINARS IN CANCER BIOLOGY is a leading journal dedicated to the dissemination of groundbreaking research in the field of cancer biology. Published by Academic Press Ltd - Elsevier Science Ltd, this esteemed journal plays a pivotal role in the academic community, boasting a prestigious impact factor and ranking within the Q1 category in Cancer Research for 2023. With an exceptional Scopus rank of #11 out of 230 in the realms of Biochemistry, Genetics, and Molecular Biology, it holds a significance that underscores its influence in advancing the understanding of cancer mechanisms and therapies. Established in 1990, the journal fosters a comprehensive platform for sharing high-quality and innovative research, critical reviews, and expert opinions aimed at professionals and researchers in the field. While not an open-access journal, it provides valuable insights that enhance the collective knowledge essential for the fight against cancer. For researchers, clinicians, and students, SEMINARS IN CANCER BIOLOGY is a crucial resource, paving the way for new discoveries and innovations in cancer treatment and prevention.